Reducing mortality from 2019-nCoV: host-directed therapies should be an option.
作者信息
Zumla Alimuddin, Hui David S, Azhar Esam I, Memish Ziad A, Maeurer Markus
机构信息
Department of Infection, Division of Infection and Immunity, University College London, London, UK; National Institute for Health Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, UK.
Department of Medicine & Therapeutics, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China.
出版信息
Lancet. 2020 Feb 22;395(10224):e35-e36. doi: 10.1016/S0140-6736(20)30305-6. Epub 2020 Feb 5.
Abstract
摘要
相似文献
1
Reducing mortality from 2019-nCoV: host-directed therapies should be an option.降低2019新型冠状病毒所致死亡率：宿主导向疗法应成为一种选择。
Lancet. 2020 Feb 22;395(10224):e35-e36. doi: 10.1016/S0140-6736(20)30305-6. Epub 2020 Feb 5.
2
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic.正在进行的 COVID-19 大流行管理临床试验。
Trends Pharmacol Sci. 2020 Jun;41(6):363-382. doi: 10.1016/j.tips.2020.03.006. Epub 2020 Apr 9.
3
Editorial: Information on the COVID-19 Pandemic continued.社论：关于新冠疫情的信息持续更新。
Transfus Apher Sci. 2020 Aug;59(4):102854. doi: 10.1016/j.transci.2020.102854. Epub 2020 Jun 26.
4
COVID-19: Main therapeutic options.新型冠状病毒肺炎：主要治疗选择
Tunis Med. 2020 Apr;98(4):299-303.
5
Treatment of COVID-19: old tricks for new challenges.2019冠状病毒病的治疗：应对新挑战的老办法
Crit Care. 2020 Mar 16;24(1):91. doi: 10.1186/s13054-020-2818-6.
6
Audio Interview: Capitalizing on Immune Responses to Covid-19.音频访谈：利用对新冠病毒的免疫反应
N Engl J Med. 2020 May 21;382(21):e93. doi: 10.1056/NEJMe2019020.
7
Use of convalescent plasma in COVID-19 patients in China.中国新冠病毒肺炎康复者恢复期血浆在新冠肺炎患者中的应用。
Transfus Clin Biol. 2020 Aug;27(3):168-169. doi: 10.1016/j.tracli.2020.05.001. Epub 2020 May 16.
8
Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19.冠状病毒药物：使用康复患者的血浆治疗新冠肺炎。
Int J Risk Saf Med. 2020;31(2):47-51. doi: 10.3233/JRS-201017.
9
Clinical findings in a patient with haemophilia A affected by COVID-19.一名甲型血友病患者感染新型冠状病毒肺炎的临床发现。
Haemophilia. 2020 Jul;26(4):e214-e216. doi: 10.1111/hae.14000. Epub 2020 Apr 13.
10
Isopathic Remedy Prepared from Convalescent Plasma as a Therapeutic Option for COVID-19?从康复期血浆制备的同种疗法药物能否作为治疗 COVID-19 的一种选择？
Homeopathy. 2020 Aug;109(3):184-185. doi: 10.1055/s-0040-1714061. Epub 2020 Jul 9.
引用本文的文献
1
Does the IL-6/KL-6 ratio distinguish different phenotypes in COVID-19 Acute Respiratory Distress Syndrome? An observational study stemmed from prospectively derived clinical, biological, and computed tomographic data.IL-6/KL-6比值能否区分新型冠状病毒肺炎急性呼吸窘迫综合征的不同表型？一项基于前瞻性收集的临床、生物学和计算机断层扫描数据的观察性研究。
PLoS One. 2025 May 21;20(5):e0321533. doi: 10.1371/journal.pone.0321533. eCollection 2025.
2
Mucosal-associated invariant T-cells in pulmonary pathophysiology.肺部病理生理学中的黏膜相关恒定T细胞
Curr Opin Pulm Med. 2025 May 1;31(3):202-210. doi: 10.1097/MCP.0000000000001163. Epub 2025 Mar 19.
3
Does the Consumption of Metformin Correlate With a Reduction in Mortality Among Patients With Type 2 Diabetes and COVID-19 in Morocco?在摩洛哥，2型糖尿病合并新冠肺炎患者服用二甲双胍与死亡率降低有关联吗？
Cureus. 2025 Jan 11;17(1):e77288. doi: 10.7759/cureus.77288. eCollection 2025 Jan.
4
Clinico-Virological Outcomes and Mutational Profile of SARS-CoV-2 in Adults Treated with Ribavirin Aerosol for COVID-19 Pneumonia.利巴韦林气雾剂治疗COVID-19肺炎成人患者的SARS-CoV-2临床病毒学结果及突变谱
Microorganisms. 2024 Jun 5;12(6):1146. doi: 10.3390/microorganisms12061146.
5
Identifying Mortality Predictors in Hospitalized COVID-19 Patients: Insights from a Single-Center Retrospective Study at a University Hospital.确定住院COVID-19患者的死亡率预测因素：来自某大学医院单中心回顾性研究的见解
Microorganisms. 2024 May 20;12(5):1032. doi: 10.3390/microorganisms12051032.
6
Impact of latent toxoplasmosis on pneumonic and non-pneumonic COVID-19 patients with estimation of relevant oxidative stress biomarkers.潜伏性弓形体感染对有或无肺部表现的 COVID-19 患者的影响，并评估相关氧化应激生物标志物。
Folia Parasitol (Praha). 2024 Apr 4;71:2024.008. doi: 10.14411/fp.2024.008.
7
Clinical and immunologic features of co-infection in COVID-19 patients, along with potential traditional Chinese medicine treatments.新型冠状病毒肺炎合并感染的临床和免疫学特征及潜在的中医药治疗。
Front Immunol. 2024 Mar 21;15:1357638. doi: 10.3389/fimmu.2024.1357638. eCollection 2024.
8
Role of biomarkers in prognostication of moderate and severe COVID-19 cases.生物标志物在中重度新冠肺炎病例预后评估中的作用。
J Family Med Prim Care. 2023 Dec;12(12):3186-3193. doi: 10.4103/jfmpc.jfmpc_423_23. Epub 2023 Dec 21.
9
A Review on Role of Inflammation in Coronavirus Disease.炎症在冠状病毒病中的作用综述
Endocr Metab Immune Disord Drug Targets. 2024;24(13):1488-1505. doi: 10.2174/0118715303265274231204075802.
10
SARS-CoV-2 infection activating a novel variant of the gene and subsequently causing development of CADASIL.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染激活该基因的一种新变体，随后导致伴有皮质下梗死和白质脑病的常染色体显性遗传性脑动脉病（CADASIL）的发展。
Arch Med Sci. 2022 Apr 4;19(6):1781-1794. doi: 10.5114/aoms/146978. eCollection 2023.
本文引用的文献
1
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
2
Coronavirus infections and immune responses.冠状病毒感染与免疫应答。
J Med Virol. 2020 Apr;92(4):424-432. doi: 10.1002/jmv.25685. Epub 2020 Feb 7.
3
The Middle East Respiratory Syndrome (MERS).中东呼吸综合征（MERS）。
Infect Dis Clin North Am. 2019 Dec;33(4):891-905. doi: 10.1016/j.idc.2019.08.001.
4
Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features.严重急性呼吸系统综合征：历史、流行病学和临床特征。
Infect Dis Clin North Am. 2019 Dec;33(4):869-889. doi: 10.1016/j.idc.2019.07.001.
5
Quality of life reported by survivors after hospitalization for Middle East respiratory syndrome (MERS).中东呼吸综合征（MERS）住院幸存者的生活质量报告。
Health Qual Life Outcomes. 2019 Jun 11;17(1):101. doi: 10.1186/s12955-019-1165-2.
6
Clinically Relevant Immune Responses against Cytomegalovirus: Implications for Precision Medicine.针对巨细胞病毒的临床相关免疫反应：对精准医疗的启示。
Int J Mol Sci. 2019 Apr 23;20(8):1986. doi: 10.3390/ijms20081986.
7
Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.呼吸道病毒治疗学的进展——第六届国际抗病毒研究学会（isirv）抗病毒小组会议报告
Antiviral Res. 2019 Jul;167:45-67. doi: 10.1016/j.antiviral.2019.04.006. Epub 2019 Apr 8.
8
Immune therapy in sepsis: Are we ready to try again?脓毒症中的免疫治疗：我们准备好再次尝试了吗？
J Intensive Care Soc. 2018 Nov;19(4):326-344. doi: 10.1177/1751143718765407. Epub 2018 Apr 4.
9
Cell therapy in acute respiratory distress syndrome.急性呼吸窘迫综合征的细胞治疗
J Thorac Dis. 2018 Sep;10(9):5607-5620. doi: 10.21037/jtd.2018.08.28.
10
Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology.致病性人类冠状病毒感染：细胞因子风暴和免疫病理学的成因及后果
Semin Immunopathol. 2017 Jul;39(5):529-539. doi: 10.1007/s00281-017-0629-x. Epub 2017 May 2.
Zotero 插件